My research work is focused on study of novel driver genes in human cancers. It entails identifying these genes through functional genetic screens, understanding their mechanistic basis, and exploring their suitability for therapeutic targeting using preclinical model systems. Towards this end, we have recently identified a novel oncogene, MECP2, which is frequently amplified in several human cancer types, and I am currently investigating the mechanistic details and therapeutic relevance of this oncogene in the context of triple negative breast cancer and ovarian cancer.